

**REQUEST FOR NAMES, EMAILS, AND ADDRESSES OF CLASS MEMBERS**

STRATEGIC CLAIMS SERVICES  
600 N. JACKSON STREET, SUITE 205  
MEDIA, PA 19063

PHONE: (610) 565-9202      EMAIL: info@strategicclaims.net      FAX: (610) 565-7985

July 9, 2026

This letter is being sent to all entities whose names have been made available to us, or which we believe may know of potential Class Members.

**We request that you assist us in identifying any individuals/entities who fit the following description:**

ALL PERSONS OR ENTITIES WHO PURCHASED SPECTRUM PHARMACEUTICALS, INC. ("SPECTRUM") COMMON STOCK BETWEEN MAY 12, 2022, AND SEPTEMBER 22, 2022, INCLUSIVE (THE "CLASS PERIOD").

Excluded from the Class are: (1) Defendants and members of their immediate families; (2) the current and former officers and directors of Spectrum during the Class Period, and members of the Individual Defendants' immediate families; (3) the legal representatives, heirs, successors, or assigns of any of the foregoing; and (4) any entity in which any Defendant has or had a controlling interest.

**The information below may assist you in finding the above requested information:**

<i>Spectrum Pharmaceuticals Securities Settlement</i> Case No. 1:22-cv-10292 (VEC) (Consolidated) Claim Filing Deadline: October 12, 2026 Exclusion Deadline: October 30, 2026 Objection Deadline: October 30, 2026 Notice To Appear Deadline: October 30, 2026 Settlement Hearing: November 20, 2026	<b>Security Identifiers:</b> CUSIP: 84763A108 ISIN: US84763A1088 SEDOL: 2982924 Ticker Symbol: NASDAQ: SPPI
---	---

**PER COURT ORDER, PLEASE RESPOND WITHIN 7 CALENDAR DAYS FROM THE DATE OF THIS NOTICE.**

Please comply in one of the following ways:

1. If you have no beneficial purchasers/owners, please advise us in writing; or
2. **Supply us with names, last known addresses, and email addresses (to the extent available)** of your beneficial purchasers/owners and we will do the emailing of the link to the electronic Notice of Pendency and Proposed Settlement of Class Action and Proof of Claim and Release ("Notice and Proof of Claim") or mailing of the Postcard Notice. Please provide us this information electronically; or
3. Advise us of how many beneficial purchasers/owners you have, and we will supply you with ample postcards to do the mailing. After the receipt of the Postcard Notices, you have seven (7) calendar days to mail them; or
4. Use the link below for the electronic Notice and Proof of Claim and email the link to each of your beneficial purchasers/owners within seven (7) calendar days after receipt of this notice.

You can bill us for any reasonable expenses actually incurred and **not to exceed:**

- **\$0.02 per link to the electronic Notice and Proof of Claim emailed, OR**
- **\$0.02 per name, address and email address** if you are providing us the records, OR
- **\$0.02 per name and address, including materials, plus postage at the rate used by the Claims Administrator**, if you are requesting the Postcard Notices and performing the mailing.

Please use the following link to the electronic Notice and Proof of Claim for emails: <https://www.strategicclaims.net/wp-content/uploads/2026/07/Ayoub-v-Spectrum-Final-Notice-and-Claim-Form.pdf>.

**All invoices must be received within 30 days of this letter.**

You are on record as having been notified of the legal matter. A copy of the Notice and Proof of Claim and other important case-related documents are available on our website at [www.strategicclaims.net/AyoubvSpectrum/](http://www.strategicclaims.net/AyoubvSpectrum/). You can also request a copy via email at [info@strategicclaims.net](mailto:info@strategicclaims.net).

Thank you for your prompt response.

Regards,

Claims Administrator  
*Spectrum Pharmaceuticals Securities Settlement*

**PLEASE NOTE - A COPY OF THE POSTCARD NOTICE IS ON THE REVERSE SIDE OF THIS LETTER.**

Please send us a statement confirming the emailing or mailing was made as directed, and please retain the names/addresses/email addresses for use in connection with any possible future notice to the Class.

Spectrum Pharmaceuticals Securities Settlement  
c/o Strategic Claims Services  
600 N Jackson St., Ste. 205  
Media, PA 19063

**Court-Ordered Legal Notice**  
(Forwarding Service Requested)

Spectrum Pharmaceuticals Securities Settlement  
c/o Strategic Claims Services  
600 N. Jackson St., Ste. 205  
Media, PA 19063

*Ayoub v. Spectrum Pharmaceuticals, Inc., et al.,  
Case No. 22-cv-10292-VEC (S.D.N.Y.)*

[www.strategicclaims.net/AyoubvSpectrum/](http://www.strategicclaims.net/AyoubvSpectrum/)

This notice contains important information about a securities class action settlement.

You may be entitled to a payment. This notice may affect your legal rights.

Please read this notice carefully.



THIS POSTCARD PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.  
VISIT [WWW.STRATEGICCLAIMS.NET/AYOUBVSPECTRUM/](http://WWW.STRATEGICCLAIMS.NET/AYOUBVSPECTRUM/) OR CALL 1-866-274-4004 FOR MORE INFORMATION.

If you purchased Spectrum Pharmaceuticals, Inc. ("Spectrum") common stock (CUSIP: 84763A108) between May 12, 2022, and September 22, 2022, inclusive, you could be entitled to a payment from a proposed settlement ("Settlement") reached in the above-captioned action ("Litigation"). Your rights may be affected by this Litigation and the Settlement. A hearing will be held on November 20, 2026, at 10:00 a.m., at the United States District Court, Southern District of New York, Daniel P. Moynihan United States Courthouse, 500 Pearl Street, New York, NY 10007 ("Settlement Hearing"), before the Honorable Valerie E. Caproni, to determine whether the proposed Settlement of the Litigation against Defendants Spectrum, Francois J. Lebel, and Thomas J. Riga for \$7 million in cash and the Plan of Allocation should be approved as fair, reasonable, and adequate; whether the Litigation should be dismissed with prejudice against Defendants, as set forth in the Stipulation of Settlement ("Stipulation") filed with the Court; and whether Lead Counsel's application for an award of attorneys' fees of up to 25% of the Settlement Amount, and expenses not to exceed \$250,000, plus interest on both amounts, and an award to Lead Plaintiff, should be granted.

If approved, the Settlement will resolve a putative class action lawsuit alleging that, in violation of the U.S. federal securities laws, the Defendants misled investors by making materially false and misleading statements and failing to disclose material information, which caused Spectrum's stock to trade at artificially inflated prices until the nature of the alleged wrongdoing was revealed, causing Spectrum's stock price to fall. Defendants deny the allegations and any liability or wrongdoing of any kind. For a full description of the proposed Settlement and your rights, and to make a claim, you may obtain the Stipulation, long-form Notice of Pendency and Proposed Settlement of Class Action ("Notice"), and the Proof of Claim and Release form ("Claim Form") by visiting the website: [www.strategicclaims.net/AyoubvSpectrum/](http://www.strategicclaims.net/AyoubvSpectrum/) ("Website") or you may request copies of the documents from the Claims Administrator by: (i) mail: Spectrum Pharmaceuticals Securities Settlement, c/o Strategic Claims Services, P.O. Box 230, 600 N. Jackson St., Ste. 205, Media, PA 19063, (ii) email at: [info@strategicclaims.net](mailto:info@strategicclaims.net), or (iii) toll-free by calling: 1-866-274-4004.

**To qualify for a payment from the Settlement, you must submit a valid Claim Form, with supporting documentation, to the Claims Administrator postmarked or submitted online no later than October 12, 2026.** Your pro rata share of the Settlement will depend on the number of valid claims, and the number, size, and timing of your transactions in Spectrum common stock. The estimated average distribution per share is approximately \$0.08, before deducting any Court-approved fees and expenses. Your actual share of the Settlement will be determined pursuant to the proposed Plan of Allocation set forth in the Notice, or other plan approved by the Court.

You will be bound by any judgment or order entered in the Litigation, regardless of whether you submit a Claim Form, unless you exclude yourself from the Class. If you exclude yourself from the Class, you cannot get money from this Settlement. If you are a Class Member and do not exclude yourself from the Class, you may object to the proposed Settlement, Plan of Allocation, and/or request for award of attorneys' fees and expenses and award to Lead Plaintiff no later than October 30, 2026. The Notice and the Website explain how to exclude yourself from the Class or how to object.

Lead Plaintiff and the Class are represented by Lead Counsel: Jeffrey P. Campisi, Kaplan Fox & Kilsheimer LLP, 800 Third Avenue, 38th Floor, New York, NY 10022, (212) 687-1980, [jcampisi@kaplanfox.com](mailto:jcampisi@kaplanfox.com). You may, but do not have to, attend the Settlement Hearing to be heard. The Court reserves the right to hold the Settlement Hearing telephonically or by other virtual means and/or change its date and/or time. Please check the Website for updates.